Online inquiry

IVTScrip™ mRNA-Human ADAMTSL3, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WK10709MR)

This product GTTS-WK10709MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ADAMTSL3 protein. This product can be used in Enteroendocrine cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_001301110.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 57188
UniProt ID P82987
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ADAMTSL3, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WK10709MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WK7709MR IVTScrip™ mRNA-Human ADAMTSL3, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ADAMTSL3
GTTS-WK19405MR IVTScrip™ mRNA-Human ANKRD18DP, (Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ANKRD18DP
GTTS-WK28299MR IVTScrip™ mRNA-Human ARHGAP4, (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ARHGAP4
GTTS-WK15970MR IVTScrip™ mRNA-Human AKIRIN2, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AKIRIN2
GTTS-WK26878MR IVTScrip™ mRNA-Human ARRDC1-AS1, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ARRDC1-AS1
GTTS-WK16760MR IVTScrip™ mRNA-Human ANXA2R, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ANXA2R
GTTS-WK22045MR IVTScrip™ mRNA-Human ARL5B, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARL5B
GTTS-WK8593MR IVTScrip™ mRNA-Human ADAM22, (Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ADAM22
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW